N-[4-(heteroarylmethyl)phenyl]-heteroarylamines

Details N-[4-(heteroarylmethyl)phenyl]-heteroarylamines N-[4-(heteroarylmethyl)phenyl]-heteroarylamines

2006-12-13

2008-05-27

Shiao, Rei-tsang (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S375000, C514S381000, C514S383000, C548S254000, C548S262200, C548S266200, C548S300100, C548S311100, C548S314700, C548S152000, C548S250000

Reexamination Certificate

active

07378433

ABSTRACT:
The present invention is concerned with compounds of formulathe N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R1is hydrogen, hydroxy, C1-6alkyl or aryl; R2is hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl, optionally substituted pyrrolidinyl or aryl; R3is hydrogen, optionally substituted C1-6alkyl or aryl; Het is an optionally substituted unsaturated heterocycle selected from imidazolyl, triazolyl, tetrazolyl and pyridinyl;is an optionally substituted unsaturated mono- or bicyclic heterocycle; and aryl is optionally substituted phenyl. The present invention also relates to processes for their preparation and compositions comprising said new compounds, as well as their use as a medicine.

REFERENCES:
patent: 5582832 (1996-12-01), Pillai et al.
patent: 5731342 (1998-03-01), Cullinan et al.
patent: 6124330 (2000-09-01), Venet et al.
patent: 6486187 (2002-11-01), Venet et al.
patent: 6833375 (2004-12-01), Venet et al.
patent: 7205312 (2007-04-01), Venet et al.
patent: 0 260 744 (1988-03-01), None
patent: 0 260 744 (1988-03-01), None
patent: 0 371 559 (1990-06-01), None
patent: WO 91/16314 (1991-10-01), None
patent: WO 96/15118 (1996-05-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/30035 (1997-08-01), None
Dockx, P., et al., “Treatment of Severe Plaque-Type Psoriasis and Acne with Oral R75251, an Inhibitor of the Retinoic Acid Metabolism: An Open Study,”18thWorld Congress of Dermatology, New York City, New York, USA, p. 52A, Jun. 12-18, 1992 [Abstract].
Roseeuw, D. et al., “Topical Inhibitors of the Retinoic Acid Biodegradation in the Treatment of Acne Vulgaris: An Update,”18thWorld Congress of Dermatology, New York City, New York, USA, p. 194A, Jun. 12-18, 1992 [Abstract].
Dhondt, A. et al., “Inhibitors of the Metabolism of Retinoic Acid in the Skin: A Novel Approach in the Treatment of Acne and Psoriasis,”2ndCongress of the European Academy of Dermatology and Venereology, p. 121, Athens, Greece, Oct. 10-13, 1991 [Abstract].
Dockx, P. et al., “Treatment of extensive psoriasis and acne with oral R 75251, an inhibitor of the retinoic acid metabolism: an open pilot study,”Belgische Vereniging van Dermatologen te Luik, Mar. 23, 1991, 1 page.
Degreef, G. et al., “Inhibitors of the Metabolism of Retinoic Acid in the Skin: A Novel Approach in the Treatment of Acne and Psoriasis,”Fifth International Psoriasis Symposium, Jul. 10-14, 1991, San Francisco, U.S.A. [Abstract].

Affiliated with

Also associated with

Rating

N-[4-(heteroarylmethyl)phenyl]-heteroarylamines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-[4-(heteroarylmethyl)phenyl]-heteroarylamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-[4-(heteroarylmethyl)phenyl]-heteroarylamines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3986599